The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Kate R. Woodworth(CDC Foundation), Sara E. Oliver(Centers for Disease Control and Prevention), Danielle Moulia(Centers for Disease Control and Prevention), Oliver Brooks, Stephen C. Hadler(The Task Force for Global Health), Sujan Reddy(Centers for Disease Control and Prevention), Grace M. Lee, H. Keipp Talbot(Marshfield Clinic), Rebecca L. Morgan(Impact), Beth P. Bell(Centers for Disease Control and Prevention), Mary E. Chamberland, Doug Campos‐Outcalt, Kathleen Dooling(Pfizer (United States)), Jennifer P. Collins(Emory University), Matthew F. Daley(Kaiser Permanente), Sarah Mbaeyi(National Center for Immunization and Respiratory Diseases), Jefferson M. Jones(National Center for Immunization and Respiratory Diseases)
Cited by 174
Related Papers
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States
|Emerging infectious diseases|2020|318
Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury — United States, October 2019
|MMWR Morbidity and Mortality Weekly Report|2019|265